Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area

Young Joo Jin, Jin Woo Lee, Jung II Lee, Sang Hoon Park, Choong Kee Park, Young Seok Kim, Sook Hyang Jeong, Yun Soo Kim, Ju Hyun Kim, Seong Gyu Hwang, Kyu Sung Rim, Hyung Joon Yim, Jae Youn Cheong, Sung Won Cho, June Sung Lee, Young Min Park, Jeong Won Jang, Chun Kyon Lee, Joo Hyun Sohn, Jin Mo Yang & 1 others Seungbong Han

Research output: Contribution to journalArticle

Abstract

Background/Aim: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virological response (EVR), end-of-treatment response (ETR), and SVR rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values >0.05) and 2/3 (all P-values >0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values>0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values>0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalJournal of Antivirals and Antiretrovirals
Volume4
Issue number4
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Ribavirin
Hepacivirus
Interferons
Genotype
Chronic Hepatitis C
Therapeutics
Viral Load
Fibrosis
Safety
Propensity Score
Liver
peginterferon alfa-2a
peginterferon alfa-2b

Keywords

  • Chronic hepatitis C
  • Pegylated interferon alfa-2a
  • Pegylated interferon alfa-2b
  • Ribavirin
  • Sustained virological response

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area. / Jin, Young Joo; Lee, Jin Woo; Lee, Jung II; Park, Sang Hoon; Park, Choong Kee; Kim, Young Seok; Jeong, Sook Hyang; Kim, Yun Soo; Kim, Ju Hyun; Hwang, Seong Gyu; Rim, Kyu Sung; Yim, Hyung Joon; Cheong, Jae Youn; Cho, Sung Won; Lee, June Sung; Park, Young Min; Jang, Jeong Won; Lee, Chun Kyon; Sohn, Joo Hyun; Yang, Jin Mo; Han, Seungbong.

In: Journal of Antivirals and Antiretrovirals, Vol. 4, No. 4, 01.12.2012, p. 80-87.

Research output: Contribution to journalArticle

Jin, YJ, Lee, JW, Lee, JII, Park, SH, Park, CK, Kim, YS, Jeong, SH, Kim, YS, Kim, JH, Hwang, SG, Rim, KS, Yim, HJ, Cheong, JY, Cho, SW, Lee, JS, Park, YM, Jang, JW, Lee, CK, Sohn, JH, Yang, JM & Han, S 2012, 'Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area', Journal of Antivirals and Antiretrovirals, vol. 4, no. 4, pp. 80-87. https://doi.org/10.4172/jaa.1000050
Jin, Young Joo ; Lee, Jin Woo ; Lee, Jung II ; Park, Sang Hoon ; Park, Choong Kee ; Kim, Young Seok ; Jeong, Sook Hyang ; Kim, Yun Soo ; Kim, Ju Hyun ; Hwang, Seong Gyu ; Rim, Kyu Sung ; Yim, Hyung Joon ; Cheong, Jae Youn ; Cho, Sung Won ; Lee, June Sung ; Park, Young Min ; Jang, Jeong Won ; Lee, Chun Kyon ; Sohn, Joo Hyun ; Yang, Jin Mo ; Han, Seungbong. / Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area. In: Journal of Antivirals and Antiretrovirals. 2012 ; Vol. 4, No. 4. pp. 80-87.
@article{ef2961f40db04b15927f302e2d13d868,
title = "Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area",
abstract = "Background/Aim: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-na{\"i}ve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virological response (EVR), end-of-treatment response (ETR), and SVR rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values >0.05) and 2/3 (all P-values >0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values>0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values>0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.",
keywords = "Chronic hepatitis C, Pegylated interferon alfa-2a, Pegylated interferon alfa-2b, Ribavirin, Sustained virological response",
author = "Jin, {Young Joo} and Lee, {Jin Woo} and Lee, {Jung II} and Park, {Sang Hoon} and Park, {Choong Kee} and Kim, {Young Seok} and Jeong, {Sook Hyang} and Kim, {Yun Soo} and Kim, {Ju Hyun} and Hwang, {Seong Gyu} and Rim, {Kyu Sung} and Yim, {Hyung Joon} and Cheong, {Jae Youn} and Cho, {Sung Won} and Lee, {June Sung} and Park, {Young Min} and Jang, {Jeong Won} and Lee, {Chun Kyon} and Sohn, {Joo Hyun} and Yang, {Jin Mo} and Seungbong Han",
year = "2012",
month = "12",
day = "1",
doi = "10.4172/jaa.1000050",
language = "English",
volume = "4",
pages = "80--87",
journal = "Journal of Antivirals and Antiretrovirals",
issn = "1948-5964",
publisher = "Omics Publishing Group",
number = "4",

}

TY - JOUR

T1 - Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area

AU - Jin, Young Joo

AU - Lee, Jin Woo

AU - Lee, Jung II

AU - Park, Sang Hoon

AU - Park, Choong Kee

AU - Kim, Young Seok

AU - Jeong, Sook Hyang

AU - Kim, Yun Soo

AU - Kim, Ju Hyun

AU - Hwang, Seong Gyu

AU - Rim, Kyu Sung

AU - Yim, Hyung Joon

AU - Cheong, Jae Youn

AU - Cho, Sung Won

AU - Lee, June Sung

AU - Park, Young Min

AU - Jang, Jeong Won

AU - Lee, Chun Kyon

AU - Sohn, Joo Hyun

AU - Yang, Jin Mo

AU - Han, Seungbong

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background/Aim: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virological response (EVR), end-of-treatment response (ETR), and SVR rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values >0.05) and 2/3 (all P-values >0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values>0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values>0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

AB - Background/Aim: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virological response (EVR), end-of-treatment response (ETR), and SVR rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values >0.05) and 2/3 (all P-values >0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values>0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values>0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

KW - Chronic hepatitis C

KW - Pegylated interferon alfa-2a

KW - Pegylated interferon alfa-2b

KW - Ribavirin

KW - Sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=84871967082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871967082&partnerID=8YFLogxK

U2 - 10.4172/jaa.1000050

DO - 10.4172/jaa.1000050

M3 - Article

VL - 4

SP - 80

EP - 87

JO - Journal of Antivirals and Antiretrovirals

JF - Journal of Antivirals and Antiretrovirals

SN - 1948-5964

IS - 4

ER -